Latest news with #CRISPRTherapeuticsAG
Yahoo
a day ago
- Business
- Yahoo
CRISPR Therapeutics AG (CRSP) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
Wall Street expects a year-over-year increase in earnings on higher revenues when CRISPR Therapeutics AG (CRSP) reports results for the quarter ended June 2025. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates. The stock might move higher if these key numbers top expectations in the upcoming earnings report. On the other hand, if they miss, the stock may move lower. While management's discussion of business conditions on the earnings call will mostly determine the sustainability of the immediate price change and future earnings expectations, it's worth having a handicapping insight into the odds of a positive EPS surprise. Zacks Consensus Estimate This company is expected to post quarterly loss of $1.47 per share in its upcoming report, which represents a year-over-year change of +1.3%. Revenues are expected to be $6.58 million, up 1165.4% from the year-ago quarter. Estimate Revisions Trend The consensus EPS estimate for the quarter has been revised 1.75% lower over the last 30 days to the current level. This is essentially a reflection of how the covering analysts have collectively reassessed their initial estimates over this period. Investors should keep in mind that an aggregate change may not always reflect the direction of estimate revisions by each of the covering analysts. Price, Consensus and EPS Surprise Earnings Whisper Estimate revisions ahead of a company's earnings release offer clues to the business conditions for the period whose results are coming out. This insight is at the core of our proprietary surprise prediction model -- the Zacks Earnings ESP (Expected Surprise Prediction). The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a more recent version of the Zacks Consensus EPS estimate. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier. Thus, a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate. However, the model's predictive power is significant for positive ESP readings only. A positive Earnings ESP is a strong predictor of an earnings beat, particularly when combined with a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold). Our research shows that stocks with this combination produce a positive surprise nearly 70% of the time, and a solid Zacks Rank actually increases the predictive power of Earnings ESP. Please note that a negative Earnings ESP reading is not indicative of an earnings miss. Our research shows that it is difficult to predict an earnings beat with any degree of confidence for stocks with negative Earnings ESP readings and/or Zacks Rank of 4 (Sell) or 5 (Strong Sell). How Have the Numbers Shaped Up for CRISPR Therapeutics? For CRISPR Therapeutics, the Most Accurate Estimate is lower than the Zacks Consensus Estimate, suggesting that analysts have recently become bearish on the company's earnings prospects. This has resulted in an Earnings ESP of -11.09%. On the other hand, the stock currently carries a Zacks Rank of #4. So, this combination makes it difficult to conclusively predict that CRISPR Therapeutics will beat the consensus EPS estimate. Does Earnings Surprise History Hold Any Clue? Analysts often consider to what extent a company has been able to match consensus estimates in the past while calculating their estimates for its future earnings. So, it's worth taking a look at the surprise history for gauging its influence on the upcoming number. For the last reported quarter, it was expected that CRISPR Therapeutics would post a loss of$1.27 per share when it actually produced a loss of -$1.58, delivering a surprise of -24.41%. Over the last four quarters, the company has beaten consensus EPS estimates two times. Bottom Line An earnings beat or miss may not be the sole basis for a stock moving higher or lower. Many stocks end up losing ground despite an earnings beat due to other factors that disappoint investors. Similarly, unforeseen catalysts help a number of stocks gain despite an earnings miss. That said, betting on stocks that are expected to beat earnings expectations does increase the odds of success. This is why it's worth checking a company's Earnings ESP and Zacks Rank ahead of its quarterly release. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported. CRISPR Therapeutics doesn't appear a compelling earnings-beat candidate. However, investors should pay attention to other factors too for betting on this stock or staying away from it ahead of its earnings release. Expected Results of an Industry Player Another stock from the Zacks Medical - Biomedical and Genetics industry, Illumina (ILMN), is soon expected to post earnings of $1.02 per share for the quarter ended June 2025. This estimate indicates a year-over-year change of +183.3%. Revenues for the quarter are expected to be $1.05 billion, down 5.8% from the year-ago quarter. Over the last 30 days, the consensus EPS estimate for Illumina has been revised 0.2% down to the current level. Nevertheless, the company now has an Earnings ESP of +1.1%, reflecting a higher Most Accurate Estimate. When combined with a Zacks Rank of #3 (Hold), this Earnings ESP indicates that Illumina will most likely beat the consensus EPS estimate. Over the last four quarters, the company surpassed consensus EPS estimates three times. Stay on top of upcoming earnings announcements with the Zacks Earnings Calendar. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report CRISPR Therapeutics AG (CRSP) : Free Stock Analysis Report Illumina, Inc. (ILMN) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
5 days ago
- Business
- Yahoo
[Latest] Global CRISPR Gene Editing Market Size/Share Worth USD 12.6 Billion by 2034 at a 13.01% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)
[220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global CRISPR Gene Editing Market size & share revenue was valued at approximately USD 3.65 Billion in 2024 and is expected to reach USD 4.10 Billion in 2025 and is expected to reach around USD 12.6 Billion by 2034, at a CAGR of 13.01% between 2025 and 2034. The key market players listed in the report with their sales, revenues and strategies are CRISPR Therapeutics AG, Agilent Technologies Inc., Thermo Fisher Scientific Inc., GeneCopoeia Inc., Synthego Corporation, System Biosciences LLC, ToolGen Inc., Rockland Immunochemicals Inc., Horizon Discovery Group PLC, Abcam Inc., Applied StemCell Inc., Cellecta Inc and others. Austin, TX, USA, July 25, 2025 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled 'CRISPR Gene Editing Market Size, Trends and Insights By Product (Kits and Reagents, Services), By Gene Editing Modality (Ex-Vivo Editing, In-Vivo Editing), By Technology (CRISPR/Cas9 Technology, CRISPR/Cas12 Technology, Prime Editing, Epigenetic Editing, Others), By Application (Therapeutic Applications, Agriculture and Livestock, Industrial Biotechnology), By End User (Biotechnology and Pharmaceutical Companies, Agricultural and Livestock Industry, Hospitals and Clinics, Others), and By Region - Global Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2025–2034' in its research database. 'According to the latest research study, the demand of the global CRISPR Gene Editing Market size & share was valued at approximately USD 3.65 Billion in 2024 and is expected to reach USD 4.10 Billion in 2025 and is expected to reach a value of around USD 12.6 Billion by 2034, at a compound annual growth rate (CAGR) of about 13.01% during the forecast period 2025 to 2034.' Click Here to Access a Free Sample Report of the Global CRISPR Gene Editing Market @ Overview As per the industry experts at CMI, Major players in the CRISPR gene editing segment such as CRISPR Therapeutics AG, Agilent Technologies Inc., Thermo Fisher Scientific Inc., and GeneCopoeia Inc., are enhancing precision gene editing via scalable platforms and solutions from synthetic biology. With the automation and genomic cloud computing these companies intend to enhance CRISPR's precision and efficacy, they will utilize AI-generated guide RNAs. Other active ventures focus on plant and agricultural biopharmaceuticals, therapeutic biopharmaceuticals, or functional genomics. Collaborations between universities, clinics, and the biotech sector are on the rise, which accelerates innovation and globalization. Compliance with FDA, EMA, ISO, ESG, and CSR requirements strengthens green laboratory sustainability initiatives. These enduring strategic focuses enable still transformative advances in CRISPR. Key Trends & Drivers The Rise in Demand for Personalized Medicine: This is the increasing need for treatments based on and tailored to an individual's genetic composition. This increases efficiency and reduces adverse drug reactions. CRISPR technology aids in this by enabling on-target, specific edits. In March 2025, a CRISPR-based therapy received expanded orphan drug designation from the FDA for treating a rare genetic liver metabolic disorder which marked a regulatory milestone. Furthermore, pharmaceutical manufacturers have several personalized CRISPR clinical programs in progress for sickle cell and retinal diseases. These initiatives highlight the increasing momentum and investment behind tailored patient-specific, gene-editing therapies. As trials expand, the clinical availability of tailored CRISPR therapies approaches reality. Growth in Agricultural Biotechnology: This concerns the application of CRISPR technology for modification of essential traits in crops like yield, climate resilience and pest resistance to solve food crises around the world. There is relaxed concern with GMO crops as emerging markets are granting less red tape than traditional GMOs to genome edited crops. In late 2024, a multinational agri-biotech consortium conducted successful pilot trials of drought resistant CRISPR maize in sub-saharan Africa. Since then, major seed companies have formed alliances aimed at bringing these next generation crops to market. The surge in the funding of agricultural startups specializing in gene editing technologies reached nearly double the amount received throughout 2024 in the first quarter of 2025. This strongly substantiates the impact and promise of CRISPR on sustainable agriculture. Request a Customized Copy of the CRISPR Gene Editing Market Report @ The Integration of Synthetic Biology: The rise of synthetic biology is a relatively more recent phenomenon within the life sciences. Synthetic biology is the infusion of CRISPR genetic modification into frameworks designated for creating biomaterials, therapeutics, and diagnostics. It promotes creativity by programming biological functions into living organisms. In January 2025, one of the leaders in the industry launched a fully automated CRISPR workstation that designs host organisms for enzyme production. In the same quarter, CRISPR editing kits meant for easier construction of sophisticated metabolic pathways were issued. These tools which permit rapid prototyping and bioproduction, are alleviating constraints in biomanufacturing. The remarkable progress made in synthetic biology is motivating the greater adoption of CRISPR technologies by the industrial and academic sectors. Report Scope Feature of the Report Details Market Size in 2025 USD 4.10 Billion Projected Market Size in 2034 USD 12.6 Billion Market Size in 2024 USD 3.65 Billion CAGR Growth Rate 13.01% CAGR Base Year 2024 Forecast Period 2025-2034 Key Segment By Product, Gene Editing Modality, Technology, Application, End User and Region Report Coverage Revenue Estimation and Forecast, Company Profile, Competitive Landscape, Growth Factors and Recent Trends Regional Scope North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America Buying Options Request tailored purchasing options to fulfil your requirements for research. (A free sample of the CRISPR Gene Editing report is available upon request; please contact us for more information.) Our Free Sample Report Consists of the following: Introduction, Overview, and in-depth industry analysis are all included in the 2024 updated report. The COVID-19 Pandemic Outbreak Impact Analysis is included in the package. About 220+ Pages Research Report (Including Recent Research) Provide detailed chapter-by-chapter guidance on the Request. Updated Regional Analysis with a Graphical Representation of Size, Share, and Trends for the Year 2025 Includes Tables and figures have been updated. The most recent version of the report includes the Top Market Players, their Business Strategies, Sales Volume, and Revenue Analysis Custom Market Insights (CMI) research methodology (Please note that the sample of the CRISPR Gene Editing report has been modified to include the COVID-19 impact study prior to delivery.) Request a Customized Copy of the CRISPR Gene Editing Market Report @ SWOT Analysis Strengths: The applicability of CRISPR technology spans over various domains, from healthcare and agriculture to diagnostics, making it easier to adopt and innovate. Unlike traditional gene editing methodologies, it is much more cost efficient, precise, and effective. Further, it undergoes fewer regulatory roadblocks. Strong competitors, coupled with increased research and development spending and greater regulatory acceptance for clinical trial approvals, also serve to propel the industry. Lastly, the core principles of the technology's design foster worldwide ingenuity, industrial adoption, and innovation. Weaknesses: Concerns from other sectors such as off target effects and ineffective delivery mechanisms pose significant ethical barriers that conflict with the acceptance of CRISPR technology. Furthermore, lack of global uniform regulations creates disputes of ownership which stifles the key players in the industry. From a public standpoint, these issues damage perception of trust and the ability to scale commercially. There are also broader societal barriers, including the overly complex therapeutic development process and high reliability costs that work counter to public adoption. Opportunities: Increased interactions between government and private organizations coupled with the advances in synthetic biology create purpose built medicine and fuel emerging markets. Focused agricultural innovations also enable wide scale adoption in developing nations. With innovations like prime editing and base editing, emerging technologies bring vast commercial prospects. Moreover, automation alongside AI powered guide RNA creates the opportunity for high precision design. Threats: Unresolved controversies, including regulatory uncertainty, ethical concerns (particularly relating to germline editing), and biosafety issues, remain looming threats. Market share might be affected by competition from TALEN and ZFN as other alternative technologies for genome editing. Clinical progress may be hampered by legal restrictions or public backlash. In addition, latent cybersecurity risks in digital genomics and the misuse of data continue to be troubling matters. Request a Customized Copy of the CRISPR Gene Editing Market Report @ Key questions answered in this report: What is the size of the CRISPR Gene Editing market and what is its expected growth rate? What are the primary driving factors that push the CRISPR Gene Editing market forward? What are the CRISPR Gene Editing Industry's top companies? What are the different categories that the CRISPR Gene Editing Market caters to? What will be the fastest-growing segment or region? In the value chain, what role do essential players play? What is the procedure for getting a free copy of the CRISPR Gene Editing market sample report and company profiles? Key Offerings: Market Share, Size & Forecast by Revenue | 2025−2034 Market Dynamics – Growth Drivers, Restraints, Investment Opportunities, and Leading Trends Market Segmentation – A detailed analysis by Types of Services, by End-User Services, and by regions Competitive Landscape – Top Key Vendors and Other Prominent Vendors Buy this Premium CRISPR Gene Editing Research Report | Fast Delivery Available - [220+ Pages] @ Regional Perspective The CRISPR Gene Editing Market can be divided across different regions such as North America, Europe, Asia-Pacific, and LAMEA. This is a cursory overview of each region: North America: Structured CRISPR research in the biotech sector of the United States, Canada, and Mexico makes a marked difference to CRISPR innovation as a whole. With global leaders in reagents as well as in Synthetic Biology, the region provides tremendous public and private funding in advanced biotech companies. With the new gene-editing firm opening its CRISPR facility in Massachusetts in February 2024, we are expecting sharp growth in North America Made Cas enzyme production. This confirms what we already knew regarding North America's advancements in commercial and clinical CRISPR usage. Europe: Countries like Germany, France, the UK, and Spain are jumping headfirst into commercial uses of CRISPR technology. With powerful sectors and public relations controlling the narrative, biosafety, ethics, and public engagement receive more than enough focus. The clinical trial commenced in Germany, with the France and Netherlands branches later allowing cross-border integration, which showcases the strength of collaborative effort when harnessed for rare blood disorder therapies. Asia Pacific: The Asia-Pacific region hosts state-of-the-art innovation centers like China, Japan, India, South Korea, New Zealand, Australia, Taiwan, and others. They are aggressively adopting CRISPR Technology in agriculture, healthcare, and bioengineering. This region is also scaling up the clinical applications and their associated governance structures. In August 2025, China achieved a significant milestone in regional self-sufficiency by deploying the first in-house CRISPR Cas12-based infectious disease screening systems. This rollout shows the increasing potential of implementing gene-editing technology at scale in Asia-Pacific. LAMEA: Other regions such as Brazil, the Middle East, and Africa fall under the LAMEA classification. These areas are beginning to adopt CRISPR technology in agriculture, public health initiatives, and even in developing organizational capacity. There is positive momentum in investment levels and regulatory sophistication. In October 2024 Brazil launched national field trials of CRISPR-edited drought resistant maize varieties, becoming the first country to have a government-backed genome editing crop initiative. Under this project, LAMEA countries are bolstering their commitment to food security and sustainable development while aiming to significantly enhance agricultural productivity. Request a Customized Copy of the CRISPR Gene Editing Market Report @ (We customized your report to meet your specific research requirements. Inquire with our sales team about customizing your report.) Still, Looking for More Information? Do OR Want Data for Inclusion in magazines, case studies, research papers, or Media? Email Directly Here with Detail Information: support@ Browse the full 'CRISPR Gene Editing Market Size, Trends and Insights By Product (Kits and Reagents, Services), By Gene Editing Modality (Ex-Vivo Editing, In-Vivo Editing), By Technology (CRISPR/Cas9 Technology, CRISPR/Cas12 Technology, Prime Editing, Epigenetic Editing, Others), By Application (Therapeutic Applications, Agriculture and Livestock, Industrial Biotechnology), By End User (Biotechnology and Pharmaceutical Companies, Agricultural and Livestock Industry, Hospitals and Clinics, Others), and By Region - Global Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2025–2034' Report at List of the prominent players in the CRISPR Gene Editing Market: CRISPR Therapeutics AG Agilent Technologies Inc. Thermo Fisher Scientific Inc. GeneCopoeia Inc. Synthego Corporation System Biosciences LLC ToolGen Inc. Rockland Immunochemicals Inc. Horizon Discovery Group PLC Abcam Inc. Applied StemCell Inc. Cellecta Inc Others Click Here to Access a Free Sample Report of the Global CRISPR Gene Editing Market @ Spectacular Deals Comprehensive coverage Maximum number of market tables and figures The subscription-based option is offered. Best price guarantee Free 35% or 60 hours of customization. Free post-sale service assistance. 25% discount on your next purchase. Service guarantees are available. Personalized market brief by author. Browse More Related Reports: CRISPR and Cas Genes Market: CRISPR and Cas Genes Market Size, Trends and Insights By Technology Type (CRISPR/Cas9, CRISPR/Cas13, CRISPR/Cas14, Others), By Delivery Method (Ex vivo, In vivo, Physical Methods, Others), By Application Area (Functional Genomics, Oncology, Infectious Diseases, Others), By Tool Type (Guide RNA, CRISPR Plasmids, Cas Nucleases, Custom CRISPR Libraries, Vectors & Cloning Kits), By Crop Type (Cereals & Grains, Fruits & Vegetables, Oilseeds & Pulses, Industrial Crops), By Disease Type (Cancer, Blood Disorders, Ophthalmic Diseases, Infectious Diseases, Others), and By Region - Global Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2025–2034 Japan Tissue Engineering Market: Japan Tissue Engineering Market Size, Trends and Insights By Type (Synthetic Scaffold Material, Biologically Derived Scaffold Material, Others), By Application (Orthopedics and Musculoskeletal, Neurology, Cardiovascular, Skin and Integumentary, Dental, Others), By End user (Hospitals and Clinics, Ambulatory Facilities), and By Region - Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2025–2034 North America Oral Care Market: North America Oral Care Market Size, Trends and Insights By Product Type (Toothbrush, Manual, Electric (Rechargeable), Battery-powered (Non-rechargeable), Others, Toothpaste, Gel, Polish, Paste, Powder, Mouthwash/Rinse, Medicated, Non-medicated, Denture Products, Cleaners, Fixatives, Floss, Others, Dental Accessories, Cosmetic Whitening Products, Fresh Breath Dental Chewing Gum, Tongue Scrapers, Fresh Breath Strips, Others, Oral Irrigators, Mouth Freshener Sprays), By Age Group (Kids, Adults, Geriatric), By Type (Countertop, Cordless), By Application (Home, Dentistry), By Sales Channel (Hypermarkets/Supermarkets, Specialty Stores, Drug Stores &Pharmacies, Convenience Stores, Online Sales Channel), and By Region - Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2025–2034 Japan Cell Cancer Vaccine Market: Japan Cell Cancer Vaccine Market Size, Trends and Insights By Vaccine Type (Preventive Cancer Vaccines, Therapeutic Cancer Vaccines, Oncolytic Viruses), By Indication (Prostate Cancer, Cervical Cancer), By Technology (Peptide-based Vaccines, Vector-based Vaccines, DNA/RNA-based Vaccines), and By Region - Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2025–2034 mRNA Cancer Vaccine Market: mRNA Cancer Vaccine Market Size, Trends and Insights By Cancer Type (Melanoma, Lung Cancer (NSCLC), Prostate Cancer, Pancreatic Cancer, Colorectal Cancer), By Application/Use Case (Therapeutic Cancer Vaccines, Preventive/Prophylactic Cancer Vaccines), By Delivery Mechanism (Lipid Nanoparticles (LNPs), Polymer-Based Carriers, Electroporation), and By Region - Global Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2025–2034 Neoantigen Cancer Vaccine Market: Neoantigen Cancer Vaccine Market Size, Trends and Insights By Product (Personalised antigen vaccine, Off-the-shelf neoantigen vaccine), By Neoantigen Type (Synthetic Long Peptide, Nucleic acid, Dendritic cell, Tumour cell), By Route of Administration (Intravenous, Intramuscular, Transdermal), and By Region - Global Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2025–2034 US Pharmaceutical Drug Delivery Market: US Pharmaceutical Drug Delivery Market Size, Trends and Insights By Route of Administration (Oral, Ocular, Pulmonary, Nasal, Injectable, Topical, Other), By Application (Cardiovascular Diseases, Diabetes, Cancer, Infectious Diseases, Others), By End-user (Hospitals, Ambulatory Services, Home Healthcare), and By Region - Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2025–2034 Peptide Cancer Vaccine Market: Peptide Cancer Vaccine Market Size, Trends and Insights By Type (Multivalent Peptide Vaccine, Peptide Cocktail Type, Personalized Peptide Vaccine, Peptide-Pulsed Dendritic Cancer Vaccine, Hybrid Peptide Vaccine), By Application (Breast Cancer, Lung Cancer, Melanoma, Prostate Cancer), and By Region - Global Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2025–2034 The CRISPR Gene Editing Market is segmented as follows: By Product Kits and Reagents Services By Gene Editing Modality Ex-Vivo Editing In-Vivo Editing By Technology CRISPR/Cas9 Technology CRISPR/Cas12 Technology Prime Editing Epigenetic Editing Others By Application Therapeutic Applications Agriculture and Livestock Industrial Biotechnology By End User Biotechnology and Pharmaceutical Companies Agricultural and Livestock Industry Hospitals and Clinics Others Click Here to Get a Free Sample Report of the Global CRISPR Gene Editing Market @ Regional Coverage: North America U.S. Canada Mexico Rest of North America Europe Germany France U.K. Russia Italy Spain Netherlands Rest of Europe Asia Pacific China Japan India New Zealand Australia South Korea Taiwan Rest of Asia Pacific The Middle East & Africa Saudi Arabia UAE Egypt Kuwait South Africa Rest of the Middle East & Africa Latin America Brazil Argentina Rest of Latin America This CRISPR Gene Editing Market Research/Analysis Report Contains Answers to the following Questions. Which Trends Are Causing These Developments? Who Are the Global Key Players in This CRISPR Gene Editing Market? What are Their Company Profile, Product Information, and Contact Information? What Was the Global Market Status of the CRISPR Gene Editing Market? What Was the Capacity, Production Value, Cost and PROFIT of the CRISPR Gene Editing Market? What Is the Current Market Status of the CRISPR Gene Editing Industry? What's Market Competition in This Industry, Both Company and Country Wise? What's Market Analysis of CRISPR Gene Editing Market by Considering Applications and Types? What Are Projections of the Global CRISPR Gene Editing Industry Considering Capacity, Production and Production Value? What Will Be the Estimation of Cost and Profit? What Will Be Market Share, Supply and Consumption? What about imports and exports? What Is CRISPR Gene Editing Market Chain Analysis by Upstream Raw Materials and Downstream Industry? What Is the Economic Impact On CRISPR Gene Editing Industry? What are Global Macroeconomic Environment Analysis Results? What Are Global Macroeconomic Environment Development Trends? What Are Market Dynamics of CRISPR Gene Editing Market? What Are Challenges and Opportunities? What Should Be Entry Strategies, Countermeasures to Economic Impact, and Marketing Channels for CRISPR Gene Editing Industry? Click Here to Access a Free Sample Report of the Global CRISPR Gene Editing Market @ Reasons to Purchase CRISPR Gene Editing Market Report CRISPR Gene Editing Market Report provides qualitative and quantitative analysis of the market based on segmentation involving economic and non-economic factors. CRISPR Gene Editing Market report outlines market value (USD) data for each segment and sub-segment. This report indicates the region and segment expected to witness the fastest growth and dominate the market. CRISPR Gene Editing Market Analysis by geography highlights the consumption of the product/service in the region and indicates the factors affecting the market within each region. The competitive landscape incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled. Extensive company profiles comprising company overview, company insights, product benchmarking, and SWOT analysis for the major market players. The Industry's current and future market outlook concerning recent developments (which involve growth opportunities and drivers as well as challenges and restraints of both emerging and developed regions. CRISPR Gene Editing Market Includes in-depth market analysis from various perspectives through Porter's five forces analysis and provides insight into the market through Value Chain. Reasons for the Research Report The study provides a thorough overview of the global CRISPR Gene Editing market. Compare your performance to that of the market as a whole. Aim to maintain competitiveness while innovations from established key players fuel market growth. Buy this Premium CRISPR Gene Editing Research Report | Fast Delivery Available - [220+ Pages] @ What does the report include? Drivers, restrictions, and opportunities are among the qualitative elements covered in the worldwide CRISPR Gene Editing market analysis. The competitive environment of current and potential participants in the CRISPR Gene Editing market is covered in the report, as well as those companies' strategic product development ambitions. According to the component, application, and industry vertical, this study analyzes the market qualitatively and quantitatively. Additionally, the report offers comparable data for the important regions. For each segment mentioned above, actual market sizes and forecasts have been given. Who should buy this report? Participants and stakeholders worldwide CRISPR Gene Editing market should find this report useful. The research will be useful to all market participants in the CRISPR Gene Editing industry. Managers in the CRISPR Gene Editing sector are interested in publishing up-to-date and projected data about the worldwide CRISPR Gene Editing market. Governmental agencies, regulatory bodies, decision-makers, and organizations want to invest in CRISPR Gene Editing products' market trends. Market insights are sought for by analysts, researchers, educators, strategy managers, and government organizations to develop plans. Request a Customized Copy of the CRISPR Gene Editing Market Report @ About Custom Market Insights: Custom Market Insights is a market research and advisory company delivering business insights and market research reports to large, small, and medium-scale enterprises. We assist clients with strategies and business policies and regularly work towards achieving sustainable growth in their respective domains. CMI provides a one-stop solution for data collection to investment advice. The expert analysis of our company digs out essential factors that help to understand the significance and impact of market dynamics. The professional experts apply clients inside on the aspects such as strategies for future estimation, forecasting or opportunity to grow, and consumer surveys. Follow Us: LinkedIn | Twitter | Facebook | YouTube Contact Us: Joel John CMI Consulting LLC 1333, 701 Tillery Street Unit 12, Austin, TX, Travis, US, 78702 USA: +1 737-734-2707 India: +91 20 46022736 Email: support@ Web: Blog: Blog: Blog: Blog: Buy this Premium CRISPR Gene Editing Research Report | Fast Delivery Available - [220+ Pages] @ in to access your portfolio
Yahoo
03-07-2025
- Business
- Yahoo
H.C. Wainwright Reaffirms Buy Rating on CRISPR Therapeutics After CTX310 Update
CRISPR Therapeutics AG (NASDAQ:CRSP) ranks among the best CRISPR stocks to buy. Following CRISPR Therapeutics AG (NASDAQ:CRSP)'s supplemental update to its Phase 1 CTX310 trial findings, H.C. Wainwright reaffirmed its Buy rating and $65 price target on the company on June 27. Pixabay/Public Domain According to the latest results, CTX310, an in vivo ANGPTL3 knockout therapy, continues to exhibit peak reductions of up to 82% in triglycerides and around 86% in LDL cholesterol at dose level four. These reductions were made without causing any discernible alterations in liver enzyme levels, preserving a safety profile in line with previous research. However, H.C. Wainwright pointed out that baseline cholesterol control measurements, the existence of only one patient at the highest dose level, and illness variability continue to limit analysis. Future updates, including disease-specific efficacy data, response levels over time, and reduced error values, would be of interest to the firm. CRISPR Therapeutics AG (NASDAQ:CRSP) is a leader in gene-editing technology that uses its proprietary gene sequencing platform to develop precise treatments for diseases that require DNA modification. While we acknowledge the potential of CRSP as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. Read More: and Disclosure: None. Sign in to access your portfolio
Yahoo
24-06-2025
- Business
- Yahoo
CRISPR Therapeutics AG (CRSP): A Bull Case Theory
We came across a bullish thesis on CRISPR Therapeutics AG (CRSP) on Two Natural Cap's Substack. In this article, we will summarize the bulls' thesis on CRSP. CRISPR Therapeutics AG (CRSP)'s share was trading at $41.52 as of 11th June. CRSP's trailing and forward P/E were 22.55 and 23.36 respectively according to Yahoo Finance. A scientist peering into a microscope, researching the next gene therapy breakthrough. CRISPR has re-entered the spotlight thanks to a groundbreaking case where the technology was used to treat Baby KJ, born with a severe genetic liver disorder caused by a CPS1 enzyme deficiency. With only a 50% survival rate in infancy, traditional treatment included heavy medication and a strict low-protein diet. But researchers rapidly developed a personalized CRISPR therapy that KJ has now received three times, allowing him to eat a regular diet and significantly reduce medication use. This marks a major milestone not only for KJ but for the broader gene-editing landscape. At its core, CRISPR-Cas9 was originally a bacterial defense mechanism that evolved to recognize and cut viral DNA. Scientists have since repurposed this system, using modified guide RNAs and engineered Cas9 proteins to target human DNA with remarkable precision. In most therapeutic uses, CRISPR creates double-stranded breaks that are imperfectly repaired by the body—helpful for knocking out malfunctioning genes, as seen with CASGEVY, the FDA-approved therapy for sickle cell disease and beta thalassemia. KJ's case went further, employing 'base editing' to fix a single-letter DNA error using a deaminase-modified CRISPR complex that swapped an adenine for a guanine, correcting the mutation without a DNA break. This was delivered via lipid nanoparticles (LNPs), offering dosing flexibility over traditional viral vectors. The success not only validates the science behind base editing but also uplifts companies like Beam, CRISPR Therapeutics, and Intellia after years of market declines. It also spotlights Danaher's Aldevron and Acuitas Therapeutics, whose platforms were instrumental in the therapy's development, underscoring the growing viability of personalized gene medicine. We previously covered a bullish thesis on CRISPR Therapeutics (CRSP) from wallstreetbets by MADD-Scientis, emphasizing Casgevy's revenue potential, strong cash runway, and optionality in oncology and cardiology. Since the coverage, the stock price has appreciated by roughly 1.3%. Two Natural Cap's thesis adds depth by spotlighting CRSP's role in a groundbreaking base-editing therapy, reinforcing the platform's adaptability. Both cases point to CRSP's leadership in curative gene editing. CRISPR Therapeutics AG (CRSP) is not on our list of the 30 Most Popular Stocks Among Hedge Funds. As per our database, 29 hedge fund portfolios held CRSP at the end of the first quarter which was 27 in the previous quarter. While we acknowledge the risk and potential of CRSP as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock. Disclosure: None. This article was originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
21-05-2025
- Business
- Yahoo
CRISPR Therapeutics AG (CRSP) Strikes $95M Deal with Sirius to Develop Blood Clot Drug
CRISPR Therapeutics AG (NASDAQ:CRSP) has entered a $95 million upfront partnership with China-based Sirius Therapeutics to co-develop an siRNA drug targeting blood clotting disorders. This marks a strategic shift for CRISPR, traditionally focused on gene editing, recognizing that siRNA's reversible gene silencing offers advantages for some conditions where permanent DNA edits are risky, such as inhibiting factor XI, a clotting protein, where gene editing could cause bleeding complications. A scientist in a laboratory working on a gene editing tool, to create treatments for rare genetic diseases. Under the deal, CRISPR Therapeutics AG (NASDAQ:CRSP) will pay $25 million upfront plus a $70 million equity investment in Sirius. Both companies will share development costs and profits equally, with CRSP handling U.S. commercialization and Sirius covering Greater China. The siRNA drug, SRSD107, showed promising Phase 1 results by reducing factor XI levels up to 95% and is advancing toward a Phase 3 trial by late 2026. CRISPR Therapeutics AG (NASDAQ:CRSP)'s CEO, Samarth Kulkarni, highlighted the complementary nature of siRNA and gene editing, stating siRNA's quicker regulatory path accelerates commercialization compared to gene editing's longer timeline. The company retains excitement about its CRISPR-based cardiovascular programs, including ANGPTL3 and lipoprotein(a) gene edits, but is open to licensing more siRNA assets from Sirius. This diversified approach aims to build a best-in-class cardiovascular franchise by applying the most appropriate technology for each target. Shortly after, Piper Sandler analyst Raghuram Selvaraju maintained an Overweight rating on CRISPR Therapeutics AG (NASDAQ:CRSP) with a $50 price target, citing the Sirius collaboration as a potential near-term revenue catalyst. While we acknowledge the potential of CRSP to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than CRSP and that has 100x upside potential, check out our report about this READ NEXT: and Disclosure: None. Sign in to access your portfolio
